IMPACT THERAP-B (07630.HK): H shares included in Shanghai-Hong Kong and Shenzhen-Hong Kong Stock Connect lists effective 7 September
NewTimeSpace News: On 7 September 2026, IMPACT Therapeutics, Inc. (stock code: 07630) voluntarily announced that, according to announcements published by the Shanghai Stock Exchange and the Shenzhen Stock Exchange respectively, the Company's H shares have been included in the eligible securities lists under the Shanghai-Hong Kong and Shenzhen-Hong Kong Stock Connect, effective from 7 September 2026.
Following the inclusion, eligible investors in Mainland China will be able to invest directly in the Company's H shares through the Shanghai Stock Exchange and the Shenzhen Stock Exchange. The Company considers that the inclusion will help further broaden its investor base and is expected to enhance the trading liquidity of its H shares.
NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
- HK Recently Listed Stocks Watch | IMPACT THERAP-B (07630.HK) down 9.59%, 13.93 million cornerstone shares to be unblocked on 13 November, ALLIST's furmonertinib misses Phase III primary endpoint
- Hong Kong Recently Listed Stocks Daily Report: Pharma and Semiconductors Take the Baton to Lead Gains, IMPACT THERAP-B Surges 27.78%; Liquidity Concentration at the Top Intensifies - 20260921
- IMPACT THERAP-B (07630.HK): Sepalna Receives Positive CHMP Opinion for First-Line Maintenance Treatment of Ovarian Cancer
- IMPACT THERAP-B (07630.HK): Interim revenue up 316.8% to RMB 105.2 million as Senaparib sales ramp up, loss narrows 29.5%
- IMPACT THERAP-B (07630.HK): Executive director and CEO increases stake with purchase of 100,000 shares, holding rises to approximately 6.564%